WCD: Tofacitinib’s benefits for psoriasis persist for 2 years

VANCOUVER – Oral tofacitinib for adults with moderate to severe plaque psoriasis demonstrated sustained efficacy and a “generally manageable” safety profile throughout 2 years of follow-up in a...